1.06
0.23 (26.99%)
| Previous Close | 0.835 |
| Open | 0.889 |
| Volume | 4,769,751 |
| Avg. Volume (3M) | 1,143,978 |
| Market Cap | 114,062,752 |
| Price / Book | 1.07 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -0.290 |
| Total Debt/Equity (MRQ) | 15.40% |
| Current Ratio (MRQ) | 3.20 |
| Operating Cash Flow (TTM) | -26.00 M |
| Levered Free Cash Flow (TTM) | -15.09 M |
| Return on Assets (TTM) | -76.34% |
| Return on Equity (TTM) | -213.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Oncolytics Biotech Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.88 |
|
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.92% |
| % Held by Institutions | 1.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Seeds Investor Llc | 31 Dec 2025 | 258,306 |
| Headinvest, Llc | 31 Dec 2025 | 44,700 |
| Badgley Phelps Wealth Managers, Llc | 31 Dec 2025 | 40,000 |
| Ball & Co Wealth Management Inc. | 31 Dec 2025 | 38,253 |
| 52 Weeks Range | ||
| Median | 10.00 (843.40%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Nov 2025 | 10.00 (843.40%) | Buy | 1.05 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |